| Host |
Monospecific Mouse |
| Klon |
ZM178 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mantle cell lymphoma |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Synthetic peptide corresponding to residues within aa 200-295 of Cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZM178 |
7 ml |
Ready-to-use |
CE/IVD |
Z2480MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM178 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mantle cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Synthetic peptide corresponding to residues within aa 200-295 of Cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZM178 |
0.5 ml |
Concentrate |
CE/IVD |
Z2480MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM178 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mantle cell lymphoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Synthetic peptide corresponding to residues within aa 200-295 of Cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZM178 |
0.1 ml |
Concentrate |
CE/IVD |
Z2480MT |
-
|
| Host |
Rabbit |
| Klon |
ZR197 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mantle cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide from C-terminus of human cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZR197 |
1.0 ml |
Concentrate |
CE/IVD |
Z2515RL |
-
|
| Host |
Rabbit |
| Klon |
ZR197 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mantle cell lymphoma. |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide from C-terminus of human cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZR197 |
7 ml |
Ready-to-use |
CE/IVD |
Z2515RP |
-
|
| Host |
Rabbit |
| Klon |
ZR197 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mantle cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide from C-terminus of human cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZR197 |
0.5 ml |
Concentrate |
CE/IVD |
Z2515RS |
-
|
| Host |
Rabbit |
| Klon |
ZR197 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Mantle cell lymphoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide from C-terminus of human cyclin D1 |
| Lokalisation |
Nucleus |
Cyclin D1
|
Zeta Corporation |
ZR197 |
0.1 ml |
Concentrate |
CE/IVD |
Z2515RT |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Cyclin D1 (CT) (Bcl-1)
|
Diagnostic Biosystems |
SP4 |
1 ml |
Concentrate |
CE/IVD |
RMAB003 |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Cyclin D1 (CT) (Bcl-1)
|
Diagnostic Biosystems |
SP4 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB003-01 |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Cyclin D1 (CT) (Bcl-1)
|
Diagnostic Biosystems |
SP4 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB003-05 |
-
|
| Host |
Rabbit |
| Klon |
SP4 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Cyclin D1 (CT) (Bcl-1)
|
Diagnostic Biosystems |
SP4 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD003 |
-
|
| Host |
Mouse |
| Klon |
HE12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
Cyclin E
|
Diagnostic Biosystems |
HE12 |
1 ml |
Concentrate |
CE/IVD |
MOB266 |
-
|
| Host |
Mouse |
| Klon |
HE12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
Cyclin E
|
Diagnostic Biosystems |
HE12 |
0.1 ml |
Concentrate |
CE/IVD |
MOB266-01 |
-
|
| Host |
Mouse |
| Klon |
HE12 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
Cyclin E
|
Diagnostic Biosystems |
HE12 |
0.5 ml |
Concentrate |
CE/IVD |
MOB266-05 |
-
|
| Host |
Mouse |
| Klon |
HE12 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
Cyclin E
|
Diagnostic Biosystems |
HE12 |
6 ml |
Ready-to-use |
CE/IVD |
PDM145 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM121 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Cyclin E (CCNE1) protein fragment (around aa 10-176) |
| Lokalisation |
Nucleus |
Cyclin E
|
Zeta Corporation |
ZM121 |
1 ml |
Concentrate |
CE/IVD |
Z2431ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM121 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Cyclin E (CCNE1) protein fragment (around aa 10-176) |
| Lokalisation |
Nucleus |
Cyclin E
|
Zeta Corporation |
ZM121 |
7 ml |
Ready-to-use |
CE/IVD |
Z2431MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM121 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Cyclin E (CCNE1) protein fragment (around aa 10-176) |
| Lokalisation |
Nucleus |
Cyclin E
|
Zeta Corporation |
ZM121 |
0.5 ml |
Concentrate |
CE/IVD |
Z2431MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM121 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Cyclin E (CCNE1) protein fragment (around aa 10-176) |
| Lokalisation |
Nucleus |
Cyclin E
|
Zeta Corporation |
ZM121 |
0.1 ml |
Concentrate |
CE/IVD |
Z2431MT |
-
|
| Host |
Rabbit |
| Klon |
SP146 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Near the C-terminus of the human cyclin E1 protein |
| Lokalisation |
Nucleus |
Cyclin E1
|
Zytomed Systems GmbH |
SP146 |
0.5 ml |
Concentrate |
RUO |
505-4462 |
-
|
| Host |
Rabbit |
| Klon |
SP146 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Near the C-terminus of the human cyclin E1 protein |
| Lokalisation |
Nucleus |
Cyclin E1
|
Zytomed Systems GmbH |
SP146 |
1 ml |
Concentrate |
RUO |
505-4464 |
-
|
| Host |
Mouse |
| Klon |
Cyst24 |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Mouse IgG1 |
Cystatin C
|
Zytomed Systems GmbH |
Cyst24 |
200 µg |
Purified |
RUO |
603-2386 |
-
|
| Host |
Mouse |
| Klon |
CAM 5.2 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified human Keratin 8 |
| Lokalisation |
Cytoplasm |
Cytokeratin
|
Zeta Corporation |
CAM 5.2 |
5 ml |
Ready-to-use |
CE/IVD |
Z2018MX |
-
|
| Host |
Mouse |
| Klon |
AE1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Acidic)
|
Diagnostic Biosystems |
AE1 |
1 ml |
Concentrate |
CE/IVD |
MOB092 |
-
|
| Host |
Mouse |
| Klon |
AE1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Acidic)
|
Diagnostic Biosystems |
AE1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB092-01 |
-
|
| Host |
Mouse |
| Klon |
AE1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Acidic)
|
Diagnostic Biosystems |
AE1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB092-05 |
-
|
| Host |
Mouse |
| Klon |
AE1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Acidic)
|
Diagnostic Biosystems |
AE1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM043 |
-
|
| Host |
Mouse |
| Klon |
AE3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Basic)
|
Diagnostic Biosystems |
AE3 |
1 ml |
Concentrate |
CE/IVD |
MOB093 |
-
|
| Host |
Mouse |
| Klon |
AE3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Basic)
|
Diagnostic Biosystems |
AE3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB093-01 |
-
|
| Host |
Mouse |
| Klon |
AE3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Basic)
|
Diagnostic Biosystems |
AE3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB093-05 |
-
|
| Host |
Mouse |
| Klon |
AE3 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Pepsin or Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin (Basic)
|
Diagnostic Biosystems |
AE3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM044 |
-
|
| Host |
Mouse |
| Klon |
CAM 5.2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, colon, prostate tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Anti-Cytokeratin, clone CAM 5.2, is derived from hybridization of mouse P3/NS-1/1-Ag4-1myeloma cells with spleen cells from BALB/c mice immunized with the human colorectal carcinoma cell line HT29 |
| Lokalisation |
Cytoplasm |
Cytokeratin (CAM 5.2)
|
Diagnostic Biosystems |
CAM 5.2 |
1 ml |
Concentrate |
CE/IVD |
MOB469 |
-
|
| Host |
Mouse |
| Klon |
CAM 5.2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, colon, prostate tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Anti-Cytokeratin, clone CAM 5.2, is derived from hybridization of mouse P3/NS-1/1-Ag4-1myeloma cells with spleen cells from BALB/c mice immunized with the human colorectal carcinoma cell line HT29 |
| Lokalisation |
Cytoplasm |
Cytokeratin (CAM 5.2)
|
Diagnostic Biosystems |
CAM 5.2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB469-01 |
-
|
| Host |
Mouse |
| Klon |
CAM 5.2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, colon, prostate tissue |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Anti-Cytokeratin, clone CAM 5.2, is derived from hybridization of mouse P3/NS-1/1-Ag4-1myeloma cells with spleen cells from BALB/c mice immunized with the human colorectal carcinoma cell line HT29 |
| Lokalisation |
Cytoplasm |
Cytokeratin (CAM 5.2)
|
Diagnostic Biosystems |
CAM 5.2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB469-05 |
-
|
| Host |
Mouse |
| Klon |
CAM 5.2 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung, colon, prostate tissue |
| Verdünnung |
- |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Anti-Cytokeratin, clone CAM 5.2, is derived from hybridization of mouse P3/NS-1/1-Ag4-1myeloma cells with spleen cells from BALB/c mice immunized with the human colorectal carcinoma cell line HT29 |
| Lokalisation |
Cytoplasm |
Cytokeratin (CAM 5.2)
|
Diagnostic Biosystems |
CAM 5.2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM181 |
-
|
| Host |
Mouse |
| Klon |
MNF116 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
MNF116 |
1 ml |
Concentrate |
CE/IVD |
MOB052 |
-
|
| Host |
Mouse |
| Klon |
MNF116 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
MNF116 |
0.1 ml |
Concentrate |
CE/IVD |
MOB052-01 |
-
|
| Host |
Mouse |
| Klon |
MNF116 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
MNF116 |
0.5 ml |
Concentrate |
CE/IVD |
MOB052-05 |
-
|
| Host |
Mouse |
| Klon |
MNF116 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
MNF116 |
6 ml |
Ready-to-use |
CE/IVD |
PDM116 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR035 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP010 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP010-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Skin |
| Verdünnung |
1:75 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Cytokeratin (Wide Spectrum )
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP010-05 |
-
|
| Host |
Rabbit |
| Klon |
EP42 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:75 - 1:150 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5
|
Biocare Medical |
EP42 |
0.1 ml |
Concentrate |
CE/IVD |
CME430A |
-
|
| Host |
Rabbit |
| Klon |
EP42 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal prostate |
| Verdünnung |
1:75 - 1:150 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5
|
Biocare Medical |
EP42 |
0.5 ml |
Concentrate |
CE/IVD |
CME430B |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Diagnostic Biosystems |
XM26 |
1 ml |
Concentrate |
CE/IVD |
MOB361 |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Diagnostic Biosystems |
XM26 |
0.1 ml |
Concentrate |
CE/IVD |
MOB361-01 |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Diagnostic Biosystems |
XM26 |
0.5 ml |
Concentrate |
CE/IVD |
MOB361-05 |
-
|
| Host |
Mouse |
| Klon |
XM26 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasm |
Cytokeratin 5
|
Diagnostic Biosystems |
XM26 |
6 ml |
Ready-to-use |
CE/IVD |
PDM139 |
-
|
| Host |
Rabbit |
| Klon |
EP42 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung squamous cell carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasmic |
Cytokeratin 5
|
Biocare Medical |
EP42 |
6 ml |
Ready-to-use |
CE/IVD |
PME430AA |
-
|